ME02300B - Anti cd37 antitijela - Google Patents
Anti cd37 antitijelaInfo
- Publication number
- ME02300B ME02300B MEP-2015-191A MEP19115A ME02300B ME 02300 B ME02300 B ME 02300B ME P19115 A MEP19115 A ME P19115A ME 02300 B ME02300 B ME 02300B
- Authority
- ME
- Montenegro
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- heavy chain
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 108020004414 DNA Proteins 0.000 claims 8
- 102000053602 DNA Human genes 0.000 claims 8
- 210000003719 b-lymphocyte Anatomy 0.000 claims 7
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 102000048426 human CD37 Human genes 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 108700026244 Open Reading Frames Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (24)
1. Himerni molekul antitjela koji se vezuje za humani CD37 i koji je definisan sa i.varijabilnim teškim lancem koji sadrži amino kiselinsku sekvencu prikazanu u SEQ ID NO: 2; ii.varijabilnim lakim lancem koji sadrži amino kiselinsku sekvencu prikazanu u SEQ ID NO: 4, iii.konstantnim teškim i lakim lancima koji su ljudskog porjekla.
2.Molekul antitjela prema zahtjevu 1, pri čemu i) konstantni teški lanac je IgGl lanac, i ii) konstantni laki lanac je kapa lanac.
3.Molekul antitjela prema zahtjevu 1 ili 2, pri čemu navedeni molekul antitjela ima jedan ili više mutacija u Fc domenu koji modulira jedan ili više efektorskih funkcija, poželjno navedena modulacija efektorske funkcije, je povećana u antitjelno zavisnoj ćelijsko posredovanoj citotoksičnosti.
4.Molekul antitjela prema zahtjevu 3, pri čemu navedena jedna ili više mutacija u Fc domenu je kombinacija supstitucija na položajima 239 i 332, ili 236 i 332, ili 236, 239 i 332, numerisane prema Kabat EU indeksu numerisanja, poželjno navedene supstitucije su I332E i S239D ili I332E i G236A, ili S239D, I332E i G236A.
5.Molekul antitjela prema bilo kom od zahtjeva 1 do 4 koji ima teški lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO: 28 i laki lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO: 30.
6.Antitjelni molekul prema bilo kom od zahtjeva 1 do 4 koji ima teški lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO: 32 i laki lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO: 34.
7.Antitjelni molekul prema bilo kom od zahtjeva 1 do 4 koji ima teški lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO:24 i laki lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO:26.
8.Antitjelo koje se vezuje za humani CD37 i ima teški lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO: 28 i laki lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO: 30.
9.Antitjelo koje se vezuje za humani CD37 i ima teški lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO: 32 i laki lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO: 34.
10. Antitjelo koje se vezuje za humani CD37 i ima teški lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO: 24 i laki lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO: 26.
11. DNK molekul koji sadrži region koji kodira varijabilni teški lanac antitjela prema zahtjevu 1 do 10, region koji kodira varijabilni laki lanac antitela prema zahtjevima 1 do 10.
12. DNK molekul prema zahtjevu 11, pri čemu navedeni varijabilni teški lanac koji kodira region je spojen za region koji kodira konstantni teški lanac ljudskog porekla, poželjno navedeni humani konstantni teški lanac je IgGl i poželjni navedeni humani konstantni teški lanac ima jedan ili više supstitucija u Fc regionu.
13. DNK molekul prema zahtjevu 12, pri čemu navedeni IgGl je kodiran sa sekvencom prikazanom u SEQ ID NO: 27 ili SEQ ID NO: 31 ili SEQ ID NO: 23.
14. DNK molekul prema zahtjevu 11, pri čemu navedeni varijabilni laki lanac koji kodira region je spojen za regijon koji kodira konstantni laki lanac ljudskog porjekla, poželjno navedeni konstantni laki lanac je kapa lanac.
15. DNK molekul prema zahtjevu 14, pri čemu navedeni kapa laki lanac je kodiran sa sekvencom prikazanom u SEQ ID NO: 29 ili SEQ ID NO: 33 ili SEQ ID NO: 25.
16.Ekspresioni vektor koji sadrži DNK molekul prema bilo kom od zahtjeva 11 do 15, poželjno vektor sadrži DNK molekul prema zahtjevu 13 i/ili DNK molekul prema zahtjevu 15.
17. Ćelija domaćina koja nosi jedan ili više vektora prema zahtjevu 16.
18. Postupak za proizvodnju antitjela prema bilo kom od zahtjeva 1 do 10, koji sadrži transfektovanje ćelije domaćina sisara sa jednim ili više vektora prema zahtjevu 16, kultivisanje ćelije domaćina i oporavak i prečišćavanje molekula antitela.
19. Farmaceutska komponzicija koja sadrži, kao aktivni sastojak, jedan ili više molekula anti-CD37 antitjela prema bilo kom od zahtjeva 1 do 10, i farmaceutski prihvatljivi nosač.
20. Farmaceutska kompozicija prema zahtjevu 19, dalje sadrži jedan ili više dodatnih terapeutskih agenasa.
21.Farmaceutska kompozicija prema zahtjevu 20, pri čemu navedeni jedan ili više terapeutskih agenasa su agensi koji ciljaju B ćeliju antigena CD20.
22. Farmaceutska kompozicija prema zahtjevu 19 do 21 za korišćenje u smanjenju B ćelijama koje iskazuju CD37 na njihovoj površini.
23.Farmaceutska kompozicija prema zahtjevu 19 do 21 za korišćenje u liječenju B ćelijske malignosti ili autoimunih ili inflamatornih oboljenja koja obuhvataju B ćelije u njihovoj patologiji, poželjno navedena malignost B ćelije je odabrana iz B ćelije ne-Hodgkinsonovog limfoma, B ćelije hronične limfocitne leukemije i multipla mijeloma.
24. Postupak smanjivanja CD37 koje iskazuju B ćelije iz populacije ćelija, koje sadrže primenu na navedene populacije ćelija molekula antitjela prema bilo kom od zahtjeva 1 do 10 ili farmaceutske komponzicije koja sadrži takav molekul antitjela, pri čemu je navedeni postupak izveden in vitro.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07114128 | 2007-08-09 | ||
| PCT/EP2008/060464 WO2009019312A2 (en) | 2007-08-09 | 2008-08-08 | Anti cd37 antibodies |
| EP08787055.6A EP2178915B1 (en) | 2007-08-09 | 2008-08-08 | Anti cd37 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02300B true ME02300B (me) | 2016-06-20 |
Family
ID=38925567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-191A ME02300B (me) | 2007-08-09 | 2008-08-08 | Anti cd37 antitijela |
Country Status (37)
| Country | Link |
|---|---|
| US (7) | US20100189722A1 (me) |
| EP (3) | EP2178915B1 (me) |
| JP (3) | JP5325216B2 (me) |
| KR (1) | KR101593403B1 (me) |
| CN (4) | CN102276724A (me) |
| AR (2) | AR071242A1 (me) |
| AU (1) | AU2008285590B2 (me) |
| BR (2) | BRPI0815369A2 (me) |
| CA (1) | CA2693464C (me) |
| CL (3) | CL2008002349A1 (me) |
| CO (1) | CO6251371A2 (me) |
| CY (1) | CY1117101T1 (me) |
| DK (1) | DK2178915T3 (me) |
| EA (2) | EA027499B1 (me) |
| EC (2) | ECSP109946A (me) |
| ES (1) | ES2555202T3 (me) |
| HK (1) | HK1220708A1 (me) |
| HR (1) | HRP20160009T1 (me) |
| HU (1) | HUE026221T2 (me) |
| IL (1) | IL202645A (me) |
| MA (1) | MA32665B1 (me) |
| ME (1) | ME02300B (me) |
| MY (1) | MY157555A (me) |
| NZ (2) | NZ600022A (me) |
| PE (3) | PE20120259A1 (me) |
| PH (1) | PH12014501812B1 (me) |
| PL (1) | PL2178915T3 (me) |
| PT (1) | PT2178915E (me) |
| RS (1) | RS54359B1 (me) |
| SG (1) | SG190657A1 (me) |
| SI (1) | SI2178915T1 (me) |
| TN (1) | TN2010000068A1 (me) |
| TW (2) | TW201512220A (me) |
| UA (2) | UA105445C2 (me) |
| UY (1) | UY31275A1 (me) |
| WO (1) | WO2009019312A2 (me) |
| ZA (1) | ZA200908758B (me) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2007014278A2 (en) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | B-cell reduction using cd37-specific and cd20-specific binding molecules |
| EP2418223A3 (en) | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Single-chain multivalent binding proteins with effector function |
| PE20120259A1 (es) * | 2007-08-09 | 2012-04-04 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| CA2700673A1 (en) * | 2007-09-24 | 2009-04-02 | Tragara Pharmaceuticals, Inc. | Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors |
| BRPI0911377A8 (pt) | 2008-04-11 | 2017-12-05 | Trubion Pharmaceuticals Inc | Imunoterápico de cd7 e combinação com quimioterápico bifuncional deste |
| SI2516468T1 (sl) * | 2009-12-23 | 2016-06-30 | Synimmune Gmbh | Protitelesa proti flt3 in postopki uporabe istih |
| NO331080B1 (no) * | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
| AU2011226672B2 (en) * | 2010-03-12 | 2015-07-23 | Immunogen, Inc. | CD37-binding molecules and immunoconjugates thereof |
| US20120189618A1 (en) * | 2010-07-16 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Superior efficacy of cd37 antibodies in cll blood samples |
| UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| US20120107317A1 (en) * | 2010-10-27 | 2012-05-03 | The University Of Hong Kong | Use of cytoplasmic c-myc for regulating immune responses |
| SG193447A1 (en) * | 2011-04-01 | 2013-10-30 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| EP2710042A2 (en) | 2011-05-16 | 2014-03-26 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| BR112014014258A2 (pt) * | 2011-12-13 | 2020-10-27 | Nordic Nanovector As. | molécula de anticorpo que se liga a cd37 humano; anticorpo; molécula de dna; vetor de expressão; célula hospedeira; método para produzir um anticorpo; composição farmacêutica; método de esgotamento de células b que expressam cd37 dentre uma população de células; radioimunoconjugado que se liga a cd37 humano; método de tratamento de uma malignidade de célula b; kit para a produção do radioimunoconjugado; e preparação injetável de anticorpo hh1 quimérico ou humanizado para uso no pré-tratamento de uma malignidade de célula b |
| KR20140143810A (ko) * | 2012-03-30 | 2014-12-17 | 이뮤노젠 아이엔씨 | Cd37 기반 치료의 효과를 증대시키는 방법 |
| US20130287797A1 (en) * | 2012-04-26 | 2013-10-31 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with bendamustine |
| JP2015517511A (ja) * | 2012-05-16 | 2015-06-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用 |
| EP2849783A1 (en) | 2012-05-16 | 2015-03-25 | Boehringer Ingelheim International GmbH | Combination of cd37 antibodies with further agents |
| EP2852388A4 (en) * | 2012-05-23 | 2016-01-13 | Univ Johns Hopkins | COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| WO2014151438A1 (en) * | 2013-03-15 | 2014-09-25 | Emergent Product Development Seattle, Llc | Multispecific anti-cd37 antibodies and related compositions and methods |
| US20160106837A1 (en) * | 2013-06-14 | 2016-04-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with chlorambucil |
| CN105722534B (zh) | 2013-08-01 | 2019-05-31 | 艾更斯司股份有限公司 | 结合cd37蛋白的抗体药物偶联物(adc) |
| US9291244B2 (en) | 2014-01-17 | 2016-03-22 | Ford Global Technologies, Llc | Nine speed automatic transmission |
| EP2966085A1 (en) | 2014-07-11 | 2016-01-13 | Boehringer Ingelheim International GmbH | Antibody IgG1 with a modified heavy chain constant region |
| CN107849144B (zh) | 2015-05-29 | 2021-09-17 | 艾吉纳斯公司 | 抗-ctla-4抗体及其使用方法 |
| BR112017026027A2 (pt) | 2015-06-08 | 2018-08-14 | Debiopharm Int Sa | combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20 |
| TR201816369T4 (tr) * | 2015-07-28 | 2018-11-21 | Forschungszentrum Borstel Leibniz Lungenzentrum | Endotoksin tayinine yönelik iyileştirilmiş bakteriyel endotoksin testi. |
| CN108699144B (zh) | 2015-08-28 | 2022-07-19 | 德彪发姆国际有限公司 | 用于检测cd37的抗体和测定 |
| US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
| CA3017776A1 (en) | 2016-03-15 | 2017-09-21 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
| US11278629B2 (en) | 2016-11-02 | 2022-03-22 | Debiopharm International, S.A. | Methods for improving anti-CD37 immunoconjugate therapy |
| IL307242A (en) | 2016-12-07 | 2023-11-01 | Agenus Inc | Anti-CTLA-4 antibodies and methods of using them |
| WO2018132506A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
| EP3595721B1 (en) | 2017-03-16 | 2025-07-09 | The General Hospital Corporation | Chimeric antigen receptors targeting cd37 |
| KR102706161B1 (ko) | 2017-03-31 | 2024-09-19 | 젠맵 홀딩 비.브이. | 이중특이적 항-cd37 항체, 모노클로날 항-cd37 항체 및 그의 사용 방법 |
| ES2996886T3 (en) * | 2017-06-27 | 2025-02-13 | Regeneron Pharma | Rodents comprising a humanized asgr1 locus |
| JP2021525735A (ja) | 2018-05-30 | 2021-09-27 | デビオファーム インターナショナル， エス． アー． | 抗ｃｄ３７免疫コンジュゲート投薬レジメン |
| US12275797B2 (en) | 2018-06-22 | 2025-04-15 | Genmab Holding B.V. | Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof |
| EP3793578A4 (en) * | 2018-06-22 | 2022-03-23 | The General Hospital Corporation | Chimeric antigen receptors targeting cd37 and cd19 |
| WO2020004337A1 (ja) * | 2018-06-27 | 2020-01-02 | 国立大学法人名古屋大学 | Ｃｄ３７特異的キメラ抗原レセプター |
| EP3847196A4 (en) | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| BR112021006055A2 (pt) | 2018-10-04 | 2021-07-20 | Genmab Holding B.V. | composição farmacêutica, uso da composição farmacêutica, e, métodos para induzir a morte celular ou para inibir o crescimento e/ou proliferação de uma célula tumoral e para tratar um indivíduo. |
| JP2022545834A (ja) * | 2019-08-30 | 2022-10-31 | クイル ピュージェット サウンド バイオセラピューティクス コーポレーション | 抗ｃｄ２０抗体、抗ｃｄ３７抗体、およびこれらの混合物 |
| EP4405398A4 (en) * | 2021-09-21 | 2025-10-29 | Qilu Puget Sound Biotherapeutics Corp | FC HETERODIMERS ALLOWING THE MANUFACTURE OF FUSION PROTEINS AND BI-SPECIFIC ANTIBODIES |
| WO2023057583A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 |
| WO2023057595A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 rew |
| AU2022368385A1 (en) | 2021-10-18 | 2024-04-11 | Daiichi Sankyo Company, Limited | Anti-cd37 antibody-drug conjugate |
| WO2024118480A1 (en) * | 2022-11-28 | 2024-06-06 | Epiphany Biosciences | Use of antiviral agents, composition of matter, combination preparations/agents to treat chronic diseases associated with epstein-barr virus and other human herpes viruses |
| WO2025083205A1 (en) | 2023-10-18 | 2025-04-24 | Debiopharm International S.A. | Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| EP0247091B1 (en) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| GB8800077D0 (en) * | 1988-01-05 | 1988-02-10 | Ciba Geigy Ag | Novel chimeric antibodies |
| EP0417193B1 (en) | 1988-05-27 | 1993-08-04 | Centocor, Inc. | Freeze-dried formulation for antibody products |
| ATE190355T1 (de) * | 1988-09-06 | 2000-03-15 | Xoma Corp | Genexpressions-elemente und herstellung von chimären maus-mensch-antikörpern |
| ATE289350T1 (de) | 1989-04-21 | 2005-03-15 | Amgen Inc | Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP0602126B1 (en) | 1991-08-14 | 2003-03-05 | Genentech, Inc. | Immunoglobulin variants for specific fc epsilon receptors |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DE69420137T2 (de) | 1993-06-03 | 1999-12-23 | Therapeutic Antibodies, Inc. | Herstellung von antikörperfragmenten |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| EP0904107B1 (en) | 1996-03-18 | 2004-10-20 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| WO1998005787A1 (en) | 1996-08-02 | 1998-02-12 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
| AU758240B2 (en) | 1998-02-25 | 2003-03-20 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| DE19911329A1 (de) | 1998-03-27 | 2000-09-21 | Benes Ivan Friedrich | Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung |
| ES2532910T3 (es) | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Variantes de anticuerpos y fragmentos de los mismos |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| JP2003514903A (ja) | 1999-11-24 | 2003-04-22 | イムノージェン インコーポレーテッド | タキサンを含有する細胞傷害薬とその治療への利用 |
| WO2001049698A1 (en) | 1999-12-29 | 2001-07-12 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2004016753A2 (en) | 2002-08-15 | 2004-02-26 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| EP1519959B1 (en) * | 2002-02-14 | 2014-04-02 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
| PT1534335E (pt) | 2002-08-14 | 2012-02-28 | Macrogenics Inc | Anticorpos específicos de fcγriib e processos para a sua utilização |
| EP3321282A1 (en) | 2002-09-27 | 2018-05-16 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| JP4768439B2 (ja) | 2002-10-15 | 2011-09-07 | アボット バイオセラピューティクス コーポレイション | 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変 |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| KR101441358B1 (ko) | 2003-05-14 | 2014-09-24 | 이뮤노젠 아이엔씨 | 약물 콘쥬게이트 조성물 |
| US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| US20050249723A1 (en) | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
| EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| SI2471813T1 (sl) | 2004-07-15 | 2015-03-31 | Xencor, Inc. | Optimirane Fc variante |
| US20060074225A1 (en) | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| AU2005304624B2 (en) | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US20080279850A1 (en) | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
| WO2007014278A2 (en) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | B-cell reduction using cd37-specific and cd20-specific binding molecules |
| WO2007041635A2 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| CN103554259B (zh) | 2005-10-12 | 2016-05-18 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| BRPI0814060A2 (pt) | 2007-07-06 | 2015-01-06 | Trubion Pharmaceuticals Inc | Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal |
| PE20120259A1 (es) * | 2007-08-09 | 2012-04-04 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| BRPI0911377A8 (pt) | 2008-04-11 | 2017-12-05 | Trubion Pharmaceuticals Inc | Imunoterápico de cd7 e combinação com quimioterápico bifuncional deste |
| CA2731255C (en) | 2008-07-21 | 2018-06-05 | David M. Goldenberg | Structural variants of antibodies for improved therapeutic characteristics |
| US20100135900A1 (en) | 2008-11-13 | 2010-06-03 | Trubion Pharmaceuticals, Inc. | Cd37 immunotherapeutic combination therapies and uses thereof |
| US20120189618A1 (en) * | 2010-07-16 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Superior efficacy of cd37 antibodies in cll blood samples |
| US20130287797A1 (en) * | 2012-04-26 | 2013-10-31 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with bendamustine |
| JP2015517511A (ja) * | 2012-05-16 | 2015-06-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用 |
| EP2849783A1 (en) * | 2012-05-16 | 2015-03-25 | Boehringer Ingelheim International GmbH | Combination of cd37 antibodies with further agents |
| US20160106837A1 (en) | 2013-06-14 | 2016-04-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with chlorambucil |
-
2008
- 2008-08-07 PE PE2011000972A patent/PE20120259A1/es active IP Right Grant
- 2008-08-07 PE PE2008001321A patent/PE20090499A1/es active IP Right Grant
- 2008-08-07 PE PE2013000843A patent/PE20140196A1/es not_active Application Discontinuation
- 2008-08-08 MY MYPI2010000565A patent/MY157555A/en unknown
- 2008-08-08 JP JP2010519473A patent/JP5325216B2/ja active Active
- 2008-08-08 EP EP08787055.6A patent/EP2178915B1/en active Active
- 2008-08-08 CN CN2011102205939A patent/CN102276724A/zh active Pending
- 2008-08-08 BR BRPI0815369-8A patent/BRPI0815369A2/pt active Search and Examination
- 2008-08-08 ME MEP-2015-191A patent/ME02300B/me unknown
- 2008-08-08 SG SG2013037619A patent/SG190657A1/en unknown
- 2008-08-08 PL PL08787055T patent/PL2178915T3/pl unknown
- 2008-08-08 CN CN201510756148.2A patent/CN105273086A/zh active Pending
- 2008-08-08 BR BRPI0823331-4A2A patent/BRPI0823331A2/pt not_active Application Discontinuation
- 2008-08-08 KR KR1020107002636A patent/KR101593403B1/ko not_active Expired - Fee Related
- 2008-08-08 CN CN200880102642A patent/CN101815725A/zh active Pending
- 2008-08-08 NZ NZ600022A patent/NZ600022A/xx not_active IP Right Cessation
- 2008-08-08 EP EP10168244A patent/EP2241577A1/en not_active Withdrawn
- 2008-08-08 EA EA201000274A patent/EA027499B1/ru not_active IP Right Cessation
- 2008-08-08 DK DK08787055.6T patent/DK2178915T3/en active
- 2008-08-08 CN CN2013102616193A patent/CN103396490A/zh active Pending
- 2008-08-08 EP EP12185691.8A patent/EP2562187B1/en active Active
- 2008-08-08 TW TW103121994A patent/TW201512220A/zh unknown
- 2008-08-08 UA UAA201303569A patent/UA105445C2/uk unknown
- 2008-08-08 CA CA2693464A patent/CA2693464C/en not_active Expired - Fee Related
- 2008-08-08 UY UY31275A patent/UY31275A1/es not_active Application Discontinuation
- 2008-08-08 NZ NZ583713A patent/NZ583713A/en not_active IP Right Cessation
- 2008-08-08 PT PT87870556T patent/PT2178915E/pt unknown
- 2008-08-08 ES ES08787055.6T patent/ES2555202T3/es active Active
- 2008-08-08 HR HRP20160009TT patent/HRP20160009T1/hr unknown
- 2008-08-08 AR ARP080103490A patent/AR071242A1/es not_active Application Discontinuation
- 2008-08-08 SI SI200831544T patent/SI2178915T1/sl unknown
- 2008-08-08 TW TW097130378A patent/TWI535733B/zh not_active IP Right Cessation
- 2008-08-08 HU HUE08787055A patent/HUE026221T2/en unknown
- 2008-08-08 WO PCT/EP2008/060464 patent/WO2009019312A2/en not_active Ceased
- 2008-08-08 EA EA201200994A patent/EA201200994A1/ru unknown
- 2008-08-08 UA UAA201002500A patent/UA103005C2/ru unknown
- 2008-08-08 US US12/672,378 patent/US20100189722A1/en not_active Abandoned
- 2008-08-08 CL CL2008002349A patent/CL2008002349A1/es unknown
- 2008-08-08 AU AU2008285590A patent/AU2008285590B2/en not_active Ceased
- 2008-08-08 RS RS20150817A patent/RS54359B1/sr unknown
-
2009
- 2009-12-09 ZA ZA200908758A patent/ZA200908758B/xx unknown
- 2009-12-10 IL IL202645A patent/IL202645A/en active IP Right Grant
-
2010
- 2010-02-08 TN TNP2010000068A patent/TN2010000068A1/fr unknown
- 2010-02-09 CO CO10014090A patent/CO6251371A2/es not_active Application Discontinuation
- 2010-02-09 MA MA32605A patent/MA32665B1/fr unknown
- 2010-02-09 EC EC2010009946A patent/ECSP109946A/es unknown
- 2010-08-18 JP JP2010183075A patent/JP5238000B2/ja active Active
- 2010-09-17 US US12/884,563 patent/US20110165153A1/en not_active Abandoned
- 2010-12-02 HK HK16108880.8A patent/HK1220708A1/zh unknown
-
2011
- 2011-06-24 CL CL2011001592A patent/CL2011001592A1/es unknown
- 2011-08-03 EC EC2011009946A patent/ECSP11009946A/es unknown
-
2012
- 2012-08-22 CL CL2012002329A patent/CL2012002329A1/es unknown
-
2013
- 2013-07-19 JP JP2013150731A patent/JP2014039541A/ja not_active Withdrawn
- 2013-08-23 US US13/974,230 patent/US20140004110A1/en not_active Abandoned
- 2013-08-23 US US13/974,226 patent/US9078879B2/en active Active
-
2014
- 2014-08-11 PH PH12014501812A patent/PH12014501812B1/en unknown
-
2015
- 2015-04-22 US US14/693,047 patent/US9932399B2/en active Active
-
2016
- 2016-01-12 CY CY20161100025T patent/CY1117101T1/el unknown
-
2017
- 2017-03-16 AR ARP170100658A patent/AR107902A2/es unknown
-
2018
- 2018-02-15 US US15/897,400 patent/US20180186876A1/en not_active Abandoned
-
2020
- 2020-11-04 US US17/088,765 patent/US20210230271A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02300B (me) | Anti cd37 antitijela | |
| RU2742691C2 (ru) | Cd3-связывающий домен | |
| JP2022177090A5 (me) | ||
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| HRP20220637T1 (hr) | Protutijela anti-komplementa c1s i njihova upotreba | |
| HRP20251181T1 (hr) | Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene | |
| JP2017536829A5 (me) | ||
| JP2020515239A5 (me) | ||
| JP2009518050A5 (me) | ||
| JP2018519263A5 (me) | ||
| FI2995315T3 (fi) | Koostumuksia ja menetelmiä hematologisten syöpien hoitamiseksi kohdistuen sirp-alfan ja cd47:n interaktioon | |
| FI3177643T5 (fi) | T-soluja aktivoivia bispesifisiä antigeeniä sitovia molekyylejä | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
| CA3130754A1 (en) | Multifunctional molecules that bind to t cell related cancer cells and uses thereof | |
| RU2013140433A (ru) | Человеческие антитела и конъюгаты антитело-препарат против cd74 | |
| HRP20250552T1 (hr) | Postupci za liječenje tumora upotrebom cd3xcd20 bispecifičnog antitijela | |
| JP2011509245A5 (me) | ||
| HRP20240149T1 (hr) | Bispecifična molekula za vezanje antigena, koji vežu cd3 i cd20, i njihove upotrebe | |
| RU2012122203A (ru) | Композиции и способы для лечения восполительных нарушений | |
| RU2014153440A (ru) | Антитела против cd26 и их применение | |
| US20250277051A1 (en) | Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof | |
| RU2015108797A (ru) | Антитела к jagged и способы их применения перекрестная ссылка на родственные заявки | |
| CN101831434B (zh) | 抗人cd45ra鼠免疫球蛋白可变区基因及用途 | |
| JPWO2022218380A5 (me) |